Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bmab1700 versus Opdivo in resected melanoma
PACTR202609462321916Phase 1Not yet recruiting
- Sponsor
- Mylan
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of Bmab1700 in melanoma (2 arms), sponsored by Mylan. Primary endpoint: Pharmacokinetic equivalence. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Bmab1700
03
Conditions
melanoma
Beyond the preview
Go deeper on PACTR202609462321916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609462321916.